S Robert Levine, MD’s Post

The Visual Function Working Group of the DRD Staging System Update, a project of the Mary Tyler Moore Vision Initiative, looked at what we know relevant to how to best measure visual function in people with diabetes and diabetic retinal disease. The working group has published their findings in the April 2024 issue of the peer-reviewed journal, Ophthalmology Science, in an article entitled: Visual Function Measurements in Eyes with Diabetic Retinopathy: An Expert Opinion on Available Measures.  Authors included working group leaders Adam R. Glassman, MS and Mohamed Ashraf Elmasry, MD PhD FRCOphth, and members: Darrell E. Baskin, MD, Mitchell Brigell, PhD, Victor Chong, MD, Quentin Davis, PhD, Luis Lesmes, PhD, Leonard A. Levin, MD, PhD, Ted Maddess, PhD, FNAI, Laura J. Taylor, BSc(Hons), Andreas Wenzel, PhD. Please click the link below to check out the article!  #Articles #Science #Research https://lnkd.in/ee92Gd3A

According the JAMA Ophthalmology's recently published the study, “Prevalence of Diabetic Retinopathy in the U.S. in 2021,” it's estimated that >25% of the 9.6 million people living with diabetes in the U.S. had diabetic retinopathy, and ~5% had vision-threatening diabetic retinopathy. These numbers are staggering. Thank you, Digital Diagnostics , for calling attention to this alarming data in your recent blog post (https://lnkd.in/gQA7VgWt). Together, we can make a real difference in people's lives!

Technological improvements , especially artificial intelligence are going to change in a radical way diabetic retinopathy screening. We have much to learn and work in the future ! Nevertheless we have to be satisfied by what we have done so far

“Current Practice and Future Options for Nonproliferative Diabetic Retinopathy,” recently published in Retina Today, highlights OcuTerra's novel small molecule selective integrin inhibitor, OTT166, updates on the Phase 2 DR:EAM clinical trial and some of the common myths about topical therapy and integrin inhibition. Read to learn more from top ophthalmology professionals like Dr. Jeffrey S. Heier, such as why he sees "potential for OTT166 to have an impact on slowing the progression to vision-threatening complications": https://bit.ly/40VqaIa

“Forecasting studies project a nearly 3-fold increase in the number of individuals in the US with diabetic retinopathy (from 5.5 million to 16.0 million) and vision-threatening diabetic retinopathy (from 1.2 million to 3.4 million) between 2005 and 2050,” according to a study published by JAMA Ophthalmology. Click here to learn more about the increasing prevalence of diabetic retinopathy and how symptoms of the disease can be mitigated or possibly even prevented with early diagnosis: https://hubs.la/Q021DbNx0 #DigitalDiagnostics #LumineticsCore #AI #Diabetes #Healthcare

In Retina Today, several leading experts in ophthalmology have shared their perspectives on nesvategrast (OTT166), our novel small molecule integrin inhibitor, as a promising candidate for the non-invasive treatment of diabetic retinopathy. Learn why Dr. Peter Kaiser views nesvategrast as a treatment that “would have tremendous impact as an easily used, patient-friendly option suitable for use in earlier stage disease.”: https://bit.ly/40VqaIa

The medical Journal JAMA Ophthalmology recently published the important review paper “Diabetic Retinopathy and Quality of Life: A Systematic Review and Meta-Analysis” by Mohammed G. Zayed, et al.. The review investigated the association between Diabetic Retinal Disease and both vision-related and general health-related Quality of Life (QoL) scales and noted that Diabetic Retinal Disease is the only major cause of visual loss worldwide that is still increasing..  Interventions to reduce the progression of Diabetic Retinal Disease at both early and more advanced stages could improve vision. https://lnkd.in/e4MK8in8

In a new Glaucoma Today article, Cara Capitena Young, MD, and Deidre St. Peter, MD, assistant professors of ophthalmology at the Sue Anschutz-Rodgers Eye Center, discuss the long-term impact of immediate versus delayed treatment of early glaucoma in the Early Manifest Glaucoma Trial. #glaucoma #ophthalmology #randomizedtrials #treatment

Preservative-free tafluprost-timolol fixed combination (PF-TTFC) can lower and even-out 24-hour intraocular pressure (IOP) for patients with open-angle glaucoma (OAG) or ocular hypertension, and improve symptoms of ocular surface disease (OSD) compared with BAK-Latanoprost, report investigators in a study published in Clinical Ophthalmology (Dove Medical Press). The topical drop may boost outcomes in cases requiring combination therapy, potentially encouraging regimen adherence, the report shows. Read more: https://brnw.ch/21wLdXJ #PFTTFC #PreservativeFreeTafluprostTimololFixedCombination #IntraocularPressure #IOP #OpenAngleGlaucoma #OAG #EyeCare #OcularHypertension #OcularSurfaceDisease #Ophthalmology #EyeHealth

Complete Overview On #Proliferative_Vitreoretinopathy_Industry Download E-PDF Report @ https://lnkd.in/eYHa9Bcg Proliferative Vitreoretinopathy (#PVR) is a significant and complex complication frequently linked to retinal detachment surgeries. This condition is characterized by the formation of membranes on the retinal surfaces, which can result in scarring and contraction, often causing the retina to detach again. Such challenges make PVR a major focus in ophthalmology. With the increasing incidence of retinal diseases and the rising number of retinal surgeries worldwide, the market for Proliferative Vitreoretinopathy #treatments is experiencing notable growth. Understanding Proliferative Vitreoretinopathy (PVR): #Research_and_Development: Ongoing research is focused on understanding the molecular mechanisms behind PVR and developing targeted therapies that can inhibit the cellular processes responsible for the proliferation and fibrosis seen in PVR. #Market_Dynamics: The market is driven by the increasing incidence of retinal diseases like diabetic retinopathy and age-related macular degeneration, both of which can lead to retinal detachment and subsequent PVR. Advances in surgical techniques and the development of new therapeutic agents aimed at preventing or managing PVR are contributing to market growth. #Pathophysiology: PVR occurs when retinal cells proliferate and migrate, forming fibrous membranes that can contract and cause retinal detachment or prevent reattachment. It often follows trauma or surgical procedures on the retina, complicating the recovery process. #Current_Treatments: The treatment landscape includes surgical interventions such as vitrectomy, where the vitreous gel is removed and replaced to allow the retina to be reattached. Anti-proliferative medications, steroids, and anti-inflammatory drugs are also being explored to manage or prevent PVR development post-surgery. #Future_Outlook: The market is poised for growth as new treatments and preventive strategies emerge, offering hope for better management of this complex condition. Enhanced diagnostic tools, combined with advanced pharmacological and surgical approaches, are expected to improve outcomes for patients with PVR. #Health #Healthcare #Solution #Research #Treatment #Linkedincommunity